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Abstract
We studied the safety and efficacy of 0 U, 50 U, 100 U, 150 U (five sites), 86 Usub and 100 Usub (three
sites) botulinum toxin type A (BoNTA; BOTOX®; Allergan, Inc., Irvine, CA, USA) for the prophylaxis
of chronic tension-type headache (CTTH). Three hundred patients (62.3% female; mean age 42.6 years)
enrolled. For the primary endpoint, the mean change from baseline in the number of TTH-free days per
month, there was no statistically significant difference between placebo and four BoNTA groups, but a
significant difference favouring placebo vs. BoNTA 150 was observed (4.5 vs. 2.8 tension headache-free
days/month; P = 0.007). All treatment groups improved at day 60. Although efficacy was not
demonstrated for the primary endpoint, at day 90, more patients in three BoNTA groups had ≥50%
decrease in tension headache days than did placebo (P ≤ 0.024). Most treatment-related adverse events
were mild or moderate, and transient. BoNTA was safe and well-tolerated in the study.

Introduction
Tension-type headache (TTH) is one of the primary headache disorders—having an overall annual prevalence as high as 38%—with 2% of patients affected on a daily or almost daily basis (1). Sensitization of
afferents within peripheral tissues (e.g. muscles) by local nociceptive mediators can give rise to increased
nociceptive afferent fibre activity, leading to central sensitization, and may be a pathogenic marker in
chronic tension-type headache (CTTH) (2–8). The exact role of peripheral and central sensitization in
CTTH is still unclear (8–10).
®

At motor neurons, botulinum toxin type A (BoNTA; BOTOX ; Allergan, Inc., Irvine, CA, USA) inhibits
exocytosis of acetylcholine from presynaptic nerve endings through proteolytic cleavage of a specific
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target protein, SNAP-25 (synaptosomal protein) with a molecular weight of 25 kDa), that is essential for
vesicle fusion with neuronal membranes leading to decreased muscle contractions (11). In preclinical
studies, BoNTA has also been shown to block the release of nociceptive mediators such as substance P,
glutamate, and calcitonin gene-related peptide (CGRP) at non-cholinergic, non-motor neurons via SNAP25 cleavage (11–14). Cui and colleagues have demonstrated that local peripheral injection of BoNTA
significantly reduces formalin-induced nociceptive behaviour in rats in a dose-related manner with an
absence of obvious muscle weakness (13). A small, open-label preliminary study of the analgesic effects
of BoNTA in humans found that while BoNTA did inhibit peripheral neuropeptide release from
nociceptive nerve fibres, its analgesic effects were reported by the authors to be limited (15). These results
may have been influenced by the model used in this study since an electrical stimulus was applied directly
to stimulate the pain nerve. The BoNTA pretreatment was only able to inhibit the peripheral nociceptive
peptide release (measured as neurogenic flare) in the volunteers. Since BoNTA does not cross the blood–
brain barrier and is not transported centrally by the nerve, there was no effect of BoNTA on hyperalgesia
or allodynia elicited by electrical stimulation. Therefore, BoNTA would not have the ability to block
electrically induced pain. In the preclinical studies, BoNTA was effective in situations where sufficient
peripheral sensitization (i.e. formalin or capsaicin) could be achieved, so BoNTA may inhibit the
peripheral release of nociceptive signals and thus reduce sensory input into the central nervous system
(CNS) (12). Further clinical studies of this effect in humans are needed to confirm the results of preclinical
studies.
BoNTA modification of pain pathways may potentially inhibit the pain associated with headache
disorders. The results of double-blind, placebo-controlled trials, open-label trials and retrospective chart
reviews show mixed evidence of efficacy that focal injections of BoNTA significantly reduce the
frequency, severity and disability associated with migraine, TTH and other types of headaches (16–30).
The varying results may be due to patient selection, the number of BoNTA treatments administered, the
injection protocol employed or the dosage range used.
The purpose of this trial was to evaluate the safety and efficacy of a single BoNTA treatment in five active
treatment groups compared with placebo for the prophylactic treatment of CTTH.
Methods
Objective
The objective of this study was to examine the safety and efficacy of a single treatment of BoNTA for the
prophylactic treatment of CTTH.
Study design
This was a double-blind, randomized, placebo-controlled, parallel-group, multicenter study conducted
from 4 January 2000 to 28 February 2001. There were 22 North American study centers (one in Canada
and 21 in the USA) and seven European study centers (three in Germany, two in the UK, one in Belgium
and one in Denmark). Prior to enrolment and subsequent randomization to BoNTA or placebo, patients
entered a 30-day baseline period during which they were screened for eligibility. During the baseline
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period patients were required to record data capturing specified characteristics of their headache episodes
and headache medication use using a paper diary. All eligible subjects who continued to meet eligibility
criteria at the end of a 30-day screening baseline period were randomized to one of six treatment groups.
Participant characteristics
Eligible participants were men or women aged 18– 65 years with a history of CTTH as defined by
International Headache Society criteria (31) (Key inclusion and exclusion criteria are outlined in Table 1).
The investigator could discontinue participants prematurely from the study for adverse events, protocol
violations, lack of efficacy, or administrative reasons (e.g. inability to continue, lost to follow-up).
Patients taking prophylactic headache medications were required to have been on a stable dose for at least
3 months prior to enrolment and had to maintain a stable dose throughout the study. The use of any
concurrent prescription or over-the-counter medication and the reason for taking it were recorded.
Intervention and protocol
®

Each vial of BOTOX (Allergan, Inc.) was stored in a freezer between −20°C and −5°C before use and
contained 100 U of botulinum toxin type A, 0.5 mg albumin (human) and 0.9 mg sodium chloride in a
sterile, vacuum-dried form without a preservative. BOTOX was reconstituted with 3 ml of the diluent,
0.9% sterile saline (without preservative). Reconstituted solutions were stored in a refrigerator until use
(within 4 h). To maintain the blinding of the study and the investigator (injector) and other staff involved
in assessing or reporting on the subject, an individual not involved with these activities was identified at
each study center to perform the dilutions and draw up the study medication.
At the injection visit (day 0), patients received a single treatment of 10 intramuscular injections of
BOTOX, placebo or both in five muscle groups (Fig. 1, Table 2). Depending on the muscle area, 0.20–
0.80 ml (3.3–40 U) was injected. Three treatment groups received BOTOX (50 U, 100 U or 150 U)
distributed in all five muscle groups; two treatment groups received BOTOX (either 86 U or 100 U) distributed in three muscle groups (and placebo in two muscle groups); and one group received placebo in
all five muscle groups (Table 2). Total BOTOX doses were 50 U, 86 Usub, 100 U, 100 Usub and 150 U
(‘sub’ identifies the groups in which only three muscle groups received active treatment); the number of
BOTOX U per muscle for each treatment group was fixed. Post-injection follow-up evaluations were
scheduled on days 30, 60, 90 and 120.
At each study visit, participants were given a week paper diary and instructed to complete it on a daily
basis throughout the study. Patients recorded the occurrence, severity, maximum severity and location of
TTH; associated headache symptoms (nausea, vomiting, increased sensitivity to light and/or noise, and
worsening head pain with physical activity); percentage of each day with headache, as calculated from the
hours awake with headache as a proportion of those hours; headache medications with dose and time of
dose; and the occurrence of non-TTH. Patients were administered the Headache Pain Specific Quality of
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Life Questionnaire, the Tension-Type Headache Impact Questionnaire and the SF-36 Health Survey to
evaluate the impact of treatment. The diaries were collected at the scheduled monthly study visits.

This study was conducted in compliance with institutional review board regulations in each participating
country, the Declaration of Helsinki, informed consent regulations of each participating country, the
recommendations of the International Headache Society for studies in the prophylactic treatment of
CTTH, and the International Conference on Harmonization guideline for Good Clinical Practice.
Outcome measures
Efficacy
The primary efficacy variable was the mean change from baseline in the number of TTH-free days per
month for the 30 days prior to day 60 (postinjection) recorded by the patient in the paper diary. The
clinical criterion for effectiveness was a 3 days/month difference between treatment groups in the mean
change from baseline for the number of TTH-free days.
Secondary efficacy measures included the percentage of patients reporting at least a 50% decrease in TTH
days; percentage of the day with headache, as calculated from the hours awake with headache as a
proportion of the hours awake; average of headache severity, as recorded in the patient diary; and
concurrent headache medication usage.
Information from measures collected during office visits included the subject’s response to treatment
[rated on a 9-point Global Assessment Scale from −4 (very marked worsening) to +4 (clearance of signs
and symptoms)]; the subject’s rating of worst, least and usual TTH-associated pain as measured on an 11point scale (0 = no pain to 10 = pain as bad as can be); and the subject’s score on a Beck Depression
Inventory. Other efficacy measures documented in the patient’s diary included days of current acute
headache medication usage per 30-day interval, average maximal headache severity per 30-day interval,
presence/absence of associated headache symptoms and non-TTH days per 30-day interval.
Safety
Adverse events. All reported adverse events were recorded, with information regarding the date of onset,
resolution date (if applicable), severity (mild, moderate or severe), duration, frequency, relationship to
study treatment, action taken regarding study treatment, treatment required (if any), and outcome included.
The relationship between an adverse event and study treatment was assessed by the investigator as none,
possible, probable or definite. A serious adverse event was defined as one that was fatal, life threatening,
or permanently disabling, or that resulted in hospitalization or prolongation of existing hospitalization.
Laboratory variables. Blood specimens were collected at the first screening visit and the last scheduled
visit (day 120 or study exit). Standard blood chemistry, electrolyte panel and haematology analyses were
performed and reported.
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Physical examination and vital signs. A physical examination was performed, and height, weight, blood
pressure, pulse rate and body temperature were measured at the first screening visit and the last scheduled
visit (day 120 or study exit). At all other study visits, pulse rate and blood pressure were measured.
Statistical analyses
Analyses were performed on data from the intent-to-treat population, which included all randomized
subjects. Subjects were analysed as randomized, regardless of which treatment they actually received, for
all except safety variables. For safety variables, subjects were analysed as actually treated. All tests were
two-sided and utilized a type I error of α= 0.05 to determine statistical significance, except that treatmentby-subgroup interactions were examined at the 0.10 level.
A key variable (mean change from baseline in TTH-free days) and visit (day 60) were identified. For the
key variable and visit, protection against multiple comparison errors was accomplished by examining Pvalues for significance between any of the five BoNTA groups and placebo only if the calculated P-value
was <0.05/5 = 0.01 (Bonferroni method). Other variables, visits and pairwise treatment comparisons were
considered supportive.
Data were summarized with descriptive statistics and/or response frequencies, including sample size,
mean, standard deviation, median, minimum and maximum. For variables with ordered response
categories and variables with a continuous response range, simultaneous comparisons among all
treatments were done with the Kruskal–Wallis test (via analysis of variance of ranks). Comparisons
between pairs of treatment groups were done with the Wilcoxon rank sum tests, even if the amongtreatment results were not significant. For the continuous variables, if the responses appeared to be
normally distributed (via the Shapiro–Wilk statistic), one-way analysis of variance methods were
considered to improve the efficiency of the inferential test. If there were significant baseline differences
between the treatments in a primary or secondary efficacy variable, a baseline covariate was included in an
analysis of covariance of the variable. For binomial data, comparisons between treatment groups were
2
done with χ tests, 2 × 6 among-group comparisons, and 2 × 2 pairwise treatment comparisons. If the
expected value of any cell in a table was <5, the affected distribution was tested with Fisher’s exact test.

Results
Patient demographics
The screening included 429 patients, 300 of whom [187/300 (62.3%) female; mean age 42.6 years (range
18–65 years)] were eligible for participation and enrolled. There were no significant demographic
differences between the treatment groups. Forty-nine patients were randomized to BoNTA 150 U, 51
patients to BoNTA 100 U, 52 patients to BoNTA 100 Usub, 51 patients to BoNTA 86 Usub, 47 patients to
BoNTA 50 U and 50 patients to placebo (Table 3). A total of 279/300 patients (93%) completed the
study. The most common reason for discontinuation was loss to follow-up [13/300 (4.3%)]. Seven BoNTA
patients discontinued the trial because of lack of efficacy. Of these patients, three were in the 150 U
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treatment group, two were in the 100 Usub treatment group, one was in the 86 Usub treatment group and
one was in the 50 U treatment group. One patient in the 100 Usub treatment group discontinued
participation for other (personal) reasons. No patient discontinued the study due to adverse events.
Headache history and medication use
All patients had a diagnosis of CTTH. The mean time since onset of CTTH was 14.7 years (range 0– 54
years) and the mean age at onset was 28.3 years (range 1–61 years). There were no significant differences
between the treatment groups in the CTTH history. Patients recorded a mean frequency of 23.0, 23.9, 23.8,
22.8, 25.5, and 25.2 TTH days per month in the BoNTA 150 U, 100 U, 100 Usub, 86 Usub, 50 U and
placebo groups, respectively (Table 3). In addition to having CTTH, 95/300 (31.6%) patients reported
having at least one migraine per month. Patients experienced a mean of 0.7 migraines per month with a
mean duration of 1.2 days per month. A total of 13/300 enrolled patients had less than 15 headache days
per month at baseline (seven in the 150 U group; two each in the 100 U, 100 Usub and 86 Usub groups)
and should not have been enrolled as per the protocol criteria. Overall, patients reported a mean headache
duration of 12.4 h per day. Most patients (87.9%) reported taking analgesic and/or prophylactic
medications including aspirin, ibuprofen, acetaminophen, acetaminophen plus codeine, non-steroidal antiinflammatory drugs, β-blockers, antidepressants and anticonvulsants for TTH pain. A total of 98 patients
(32.7%) reported taking concomitant prophylactic headache medications. Patients in the BoNTA 150 U,
100 U, 100 Usub, 86 Usub, 50 U and placebo groups used acute headache pain medication for a mean of
8.7, 10.3, 9.8, 11.9, 8.8 and 8.5 days, respectively, during the 30-day baseline period. There were no
statistically significant differences between the treatment groups in their use of acute headache pain
medication at baseline. There were 111/300 patients (37%) who used headache pain medication for 16 or
more days during the baseline period. At baseline, most patients [195/300 (65%)] did not report associated
symptoms with their headaches; however, the rest [105/300 (35%)] reported one or more associated
symptoms with some of their headaches. These symptoms included sensitivity to light [68/300 (22.7%)],
sensitivity to sound [49/300 (16.3%)], nausea [15/300 (5%)] and vomiting [2/300 (0.7%)]. Pain associated
with TTH was most often reported as bilateral [182/ 300 (60.7%)] and localized to either the front of the
head [202/300 (67.3%)] or the back of the head [161/ 300 (53.7%)]. According to the investigator
assessment, patients in the 100 U group (43.1%) had a significantly higher incidence of pain in the
cervical region compared with patients in the other groups (14.0–29.8%; P = 0.015).
Efficacy
Primary variable: mean change from baseline in the number of TTH-free days
At baseline, two of the five BoNTA treatment groups, BoNTA 100 U (6.5 days; P = 0.001) and 86 Usub
(5.3 days; P = 0.008), had a significantly higher mean frequency of headache-free days (3.3 days) than the
placebo group (Table 4). For the primary endpoint, there was no difference between placebo and four of
the BoNTA groups (50 U, 100 U, 86 Usub and 100 Usub) but a statistically significant difference favoring
placebo compared with the BoNTA 150 U group was observed (4.5 vs. 2.8 tension headache-free days per
month) (Fig. 2). All groups demonstrated improvement at the day 60 primary endpoint.
Secondary variables
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Reduction of ≥50% of TTH days. No significant differences were found in the number of patients reporting
a decrease of 50% or more headache days at day 60, the primary endpoint. However, at day 90,
significantly larger percentages of patients in the BoNTA 100 U group [15/47 (31.9%); P = 0.017], the
100 Usub group [15/49 (30.6%); P = 0.024] and the BoNTA 86 Usub group [15/47 (31.9%); P = 0.017]
reported a 50% decrease in TTH days compared with the placebo group [6/50 (12.0%)] (Fig. 3).

Percentage of the day with headache. There were no significant differences at day 60 in the percentage of
the day with headache, calculated from hours awake and hours awake with headache as reported in the
patient diary. The mean decrease from baseline was -6.8%, -3.0%, -6.5%, -4.0%, -5.0% and -4.7% for
BoNTA 150 U, 100 U, 100 Usub, 86 Usub, 50 U and placebo groups, respectively.
Average usual headache severity. There were no significant differences in the average usual headache
severity at any time point. At day 60, the mean decrease was -0.1, -0.1, -0.2, -0.2, -0.2, and -0.1 for
BoNTA 150 U, 100 U, 100 Usub, 86 Usub, 50 U and placebo groups, respectively.

Other efficacy measures
At day 60, fewer patients in the BoNTA 150 U group reported a decrease of three or more TTH days
compared with the BoNTA 86 Usub group [13/48 (27.1%) vs. 27/47 (57.4%); P = 0.003]. There were no
significant differences between placebo and any BoNTA group in the other efficacy measures (subject’s
rating of headache pain, treatment assessment, global assessment, Beck Depression Inventory, days of
concurrent headache medication usage, average maximal headache severity, associated headache
symptoms and non-TTHs) at day 60 or any other follow-up visit. A decrease in phonophobia, photophobia
(except BoNTA 50 U) and headache symptoms worsening with physical activity was noted for all groups.
There were no significant differences between the groups in the Headache Pain Specific Quality of Life
Questionnaire, the Tension-Type Headache Impact Questionnaire, and the SF-36 Health Survey (at day
60). There were no notable findings between the groups in the subgroup efficacy analyses.
Safety
Adverse events were reported for 61.7% (29/47) of BoNTA 150 U patients, 64.7% (33/51) of BoNTA 100
U, 63.5% (33/52) of 100 Usub, 54.9% (28/51) of BoNTA 86 U, 51.0% (25/49) of BoNTA 50 U and
52.0% (26/50) of placebo patients. The most frequently reported adverse events across all treatment
groups were respiratory infection [10.7% (32/300)], neck pain [8.0% (24/300)] and muscular weakness
[7.7% (23/300)]. Among 300 patients there were 41 adverse events reported as severe. Severe adverse
events included seven, 11, five, four, seven and seven for the BoNTA 150 U, 100 U, 100 USub, 86 USub,
50 U and placebo groups, respectively.
Treatment-related adverse events were reported for 32.0% (96/300) of patients overall. There were no
differences among the groups in the incidence of subjects reporting treatment-related adverse events
(Table 5). The most frequently reported treatment-related adverse events were muscular weakness [20/
300 (6.7%)] and neck pain [16/300 (5.3%)]. There were no significant differences between any BoNTA
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group and placebo in the incidence of treatment-related adverse events except the overall incidence of the
100 U group [23/51 (45.1%) vs. 11/50 (22.0%); P = 0.014]. A consistent dose-response for these
treatment-related adverse events was not apparent, but the BoNTA 100 U group did report the greatest
incidence of muscular weakness, neck rigidity, neck pain, headache and pain. Most treatment-related
adverse events were either mild or moderate in severity and transient in nature, and most patients had
recovered without sequelae at the time that the study ended.
There was no significant difference in the analysis of all BoNTA groups combined vs. placebo in the
incidence of all adverse events or treatment-related adverse events. There were no clinically relevant
differences among the groups in changes from screening to study exit for laboratory variables or vital
signs. No subject died during the study. The five serious adverse events were worsening of headache, redislocation of left shoulder, chest pain, palpitation (100 U group) and emotional lability (50 U). None of
the serious adverse events was considered treatment related.

Discussion
The results of this clinical study suggest that BoNTA is a safe, well-tolerated intervention in patients with
CTTH. No discontinuations due to adverse events occurred, nor were any treatment-related serious
adverse events reported. The BoNTA patients, especially those treated with 100 U (but not those treated
with 150 U) did have a greater percentage of transient, treatment-related, muscular weakness and neck
pain, which are known to be associated with BoNTA injections.
As a result of this intervention most patients evaluated in this study had more TTH-free days. The efficacy
of BoNTA in the prophylactic treatment of CTTH compared with a placebo treatment was not
confirmed in this study at day 60, the primary efficacy endpoint. However, at day 90 there was a
significant effect of BoNTA treatment on the percentage of patients reporting a 50% decrease in headache
days for several BoNTA dose groups, suggesting that perhaps a longer primary endpoint than 60 days may
be warranted. The results of secondary and other efficacy measures did not show that BoNTA was
significantly more effective than placebo, although improvement in most secondary and other efficacy
measures was observed. The ability to differentiate BoNTA from placebo may have been confounded due
to the uneven randomization (32) or due to the fact that patients were allowed to take acute headache pain
medication as needed to treat their headaches, thereby potentially aborting or diminishing their headache
characteristics.
BoNTA has demonstrated antinociceptive activity in patients with cervical dystonia, spasticity and chronic
musculoskeletal pain disorders in clinical trials (33–37), suggesting that BoNTA may have analgesic
effects. BoNTA inhibition of the release of nociceptive molecules has been demonstrated in several
preclinical studies (12–14) and BoNTA administration has been shown to attenuate pain behaviour in a rat
model (13). These effects have yet to be demonstrated in humans (15). BoNTA efficacy as prophylactic
treatment of TTH has been assessed in several small controlled trials, but the evidence of a treatment
effect has thus far been mixed or lacking (17, 23, 25, 27, 30, 38). The reasons for the lack of efficacy of
BoNTA treatment of CTTH in this trial may be related to the injection protocol, the BoNTA dosage range,
the patient population or ineffectiveness in this patient population.
Published version available at doi:10.1111/j.1468-2982.2006.01114.x
Silberstein SD, Göbel H, Jensen R, Elkind AH, DeGryse R, Walcott JMcM & Turkel C. Botulinum toxin type A in the prophylactic treatment of chronic
tension-type headache: a multicenter, double-blind, randomized, placebo-controlled, parallel-group study. Cephalalgia 2006; 26:790–800. Copyright ©
Blackwell Publishing Ltd.

Injection protocol
The injection protocol of this trial followed a fixed-site approach for TTH. Blumenfeld and colleagues
(39) recommend a follow-the-pain approach for BoNTA treatment of TTH injecting the frontalis
(2.5 U each, five sites on each side), temporalis (2.5 U each, four sites on each side), occipitalis (2.5–5 U
on each side), trapezius (7.5–15 U on each side), semispinalis capitis (7.5–15 U on each side) and/or
splenius capitis muscles, as deemed appropriate (21).
The current study protocol did not include occipitalis injections and it did not use as many sites for
BoNTA in various muscle groups (21, 26) (Table 2). With 60–75% of patients describing frontal head
pain and 50–60% of patients describing pain in the back of the head, the addition of more frontalis
injection sites, the addition of occipital injection sites and an increase in the total BoNTA U injected in
these sites might also have had an impact on BoNTA efficacy. Only 147/300 patients (the BoNTA 50, 100
and 150 U groups) received BoNTA injections into all five muscle sites.
BoNTA dosage range
Recent large, randomized, placebo-controlled BoNTA studies in patients with chronic headache disorders
suggest that repeated BoNTA treatment between 105 U and 260 U, a higher dose range than those used in
this study, may lead to better results (28, 29), although there are no such indications in the present study as
fairly low doses of 100 U or 86 U demonstrated a better treatment effect than 150 U.
Patient population
Given that a large number of patients in this study reported concurrent migraine symptoms, such as
sensitivity to light and sound, nausea and vomiting, and the numbers of patients reporting migraine
headaches (95/300), it is likely that the patients in this study were not suffering exclusively from CTTH
but also had coexisting infrequent migraine headaches similar to other TTH populations. In addition, the
patients in this study were required to be on stable doses of prophylactic headache medications for at least
3 months prior to the initiation of BoNTA treatment and could continue their prophylactic regimen
throughout the course of the trial. The additional effect of concurrent prophylactic headache medication
could have confounded the ability to assess a BoNTA treatment effect.

Conclusions
BoNTA treatment of CTTH in a dose range of 50 U to 150 U was shown to be safe and well tolerated. For
tension headache-free days per month, all groups improved at the day 60 primary endpoint. There was no
statistically significant difference between placebo and four BoNTA groups, but a significant difference
favoring placebo vs. BoNTA 150 U was observed. At day 90, significantly more patients reported a 50%
decrease in headache days in several BoNTA groups, suggesting that a longer period of evaluation may be
needed to see a treatment effect. The failure of BoNTA to demonstrate efficacy in this trial may be related
to the injection protocol, the BoNTA dosage range, the patient population, the use of concomitant
Published version available at doi:10.1111/j.1468-2982.2006.01114.x
Silberstein SD, Göbel H, Jensen R, Elkind AH, DeGryse R, Walcott JMcM & Turkel C. Botulinum toxin type A in the prophylactic treatment of chronic
tension-type headache: a multicenter, double-blind, randomized, placebo-controlled, parallel-group study. Cephalalgia 2006; 26:790–800. Copyright ©
Blackwell Publishing Ltd.

prophylactic headache medication or a lack of a clinically relevant effect in CTTH. BoNTA may not be an
effective prophylactic treatment of CTTH, but further study may provide insight into appropriate study
parameters and a possible treatment effect.
Dosing and results reported in this study are specific to the formulation of botulinum toxin type A
manufactured by Allergan, Inc. (Irvine, CA, USA). The Allergan, Inc. formulation is not interchangeable
with other botulinum toxin products and cannot be converted by using a dose ratio.

BOTOX CTTH Study Group
Andrew Blumenfeld, MD (California); Roger Cady, MD (Missouri); Joanna Cooper, MD (California);
James Couch, MD (Oklahoma); Seymour Diamond, MD (Illinois); Hans-Christoph Diener, MD
(Germany); Marek J. Gawel, MD (Canada); Peter Goadsby, MD, PhD (UK); Jerome Goldstein, MD
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(Texas); Alexander Mauskop, MD (New York); Volker Pfaffenrath, MD (Germany); Sid Rosenblatt, MD
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Elliott Schulman, MD (Pennsylvania); Fred Sheftell, MD (Connecticut); Timothy Smith, MD (Missouri);
Egilius Spierings, MD, PhD (Massachusetts); Stuart Stark, MD (Virginia); Timothy Steiner, MB, PhD
(UK); Paul Winner, DO (Florida).
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Figure 1
Location of injection sites. Adapted, with permission, from Nucleus Medical Art
(http://www.nucleusinc.com).

Figure 2
Mean change from baseline in the number of tension-type headache-free days at day 60.
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Figure 3
Percentage of patients with a decrease of 50% or more in tension-type headache days.

Table 1
Key inclusion and exclusion criteria
Key inclusion criteria

Key exclusion criteria
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Patients who experienced a stable
headache frequency and severity
for 6 months prior to and including
the screening period

Any medical condition or the use of any agent that may put the
participant at risk with exposure to BoNTA (e.g. neuromuscular
disorders, aminoglycoside antibiotics, curare-like agents, or other
agents that might interfere with neuromuscular function)

Patients who for 6 months prior to and
including the screening period
experienced an average headache
frequency of 15 days or more per
month, as confirmed by their
history and by their headache diary

Symptomatic medication overuse (defined as use of acute headache
analgesics on more than 15 days per month and in excess of 100
aspirin-equivalent tablets per month or use of butalbital or
ergotamine combinations on more than 3 days per week or regular
use of narcotic analgesics or excessive use of caffeine-containing
products)

Participants who were able to
distinguish tension-type headaches
from non-tension-type headaches
and follow study instructions

More than 1 migraine headache per month for the 6 months prior to
screening or during the 1-month screening period or the presence
of cluster headache or cranial neuralgias including postherpetic
neuralgia
Consistently refractory to multiple acute therapies for the treatment of
CTTH
On prophylactic headache medications for less than 3 months
immediately prior to the day-30 visit
Injection of anaesthetics or steroids into the muscles to be injected in the
month immediately prior to the day-30 visit
Previous therapy with botulinum toxin of any serotype
Women who were pregnant, nursing, or planning a pregnancy during the
study or who are unable or unwilling to use a reliable form of
contraception during the study
A condition or situation that, in the investigator ’s opinion, may have put
the patient at significant risk, confound the study results, or
significantly interfered with the patient participating in the study

Table 2
Injection protocol
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Muscle
Frontalis
(2 sites)

Sternocleidomastoid
(2 sites)

Upper trapezius
(2 sites)

Splenius capitis
(2 sites)

Anterior temporalis
(2 sites)

3.3 U
0.20 ml

13.3 U
0.80 ml

12 U
0.72 ml

12 U
0.72 ml

9.3 U
0.56 ml

BoNTA 86
Usub

10 U

40 U

36 U

0.0 U

0.0 U

BoNTA 100 U

0.20 ml
6.7 U
0.20 ml

0.80 ml
26.7 U
0.80 ml

0.72 ml
24 U
0.72 ml

0.72 ml
24 U
0.72 ml

0.56 ml
18.7 U
0.56 ml

BoNTA 100
Usub

0U

0U

36 U

36 U

28 U

0.20 ml
10 U
0.20 ml
0U
0.20 ml

0.80 ml
40 U
0.80 ml
0U
0.80 ml

0.72 ml
36 U
0.72 ml
0U
0.72 ml

0.72 ml
36 U
0.72 ml
0U
0.72 ml

0.56 ml
28 U
0.56 ml
0U
0.56 ml

Treatment group
BoNTA 50 U

BoNTA 150 U
Placebo
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Table 3
Tension-type headache (TTH) characteristics at baseline
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Table 4
Tension-type headache-free days at baseline
________________________________________________________________
P-value
vs. placebo
Treatment group
Mean
Median
at baseline
_________________________________________________________________________________
BoNTA 150 U
BoNTA 100 U
BoNTA 100 Usub
BoNTA 86 Usub
BoNTA 50 U
Placebo

5.4
6.5
5.3
5.3
4.8
3.3

2.0
6.0
3.0
4.5
2.0
0.0

0.065
0.001*
0.027
0.008*
0.133
---

________________________________________________________________
*P ≤0.01.

Table 5
Treatment-related adverse events reported in at least 3% of patients in any treatment group, by number
(%) of subjects

Preferred term

BoNTA
150 U
n = 47

100 U
n = 51

100 Usub
n = 52

86 Usub
n = 51

50 U
n = 49

Placebo
n = 50

Overall
Muscular weakness
Neck rigidity
Neck pain
Headache
Pain
Dizziness
Injection-site pain
Dysphagia
Paraesthesia
Asthenia
Hypertonia
Nausea
Pharyngitis
Injection-site burning

13 (27.7)
3 (6.4)
1 (2.1)
3 (6.4)
0 (0.0)
1 (2.1)
0 (0.0)
1 (2.1)
0 (0.0)
0 (0.0)
0 (0.0)
2 (4.3)
0 (0.0)
0 (0.0)
1 (2.1)

23 (45.1)
10 (19.6)
5 (9.8)
4 (7.8)
4 (7.8)
4 (7.8)
4 (7.8)
1 (2.0)
1 (2.0)
0 (0.0)
2 (3.9)
0 (0.0)
0 (0.0)
0 (0.0)
0 (0.0)

16 (30.8)
2 (3.8)
0 (0.0)
2 (3.8)
2 (3.8)
3 (5.8)
1 (1.9)
1 (1.9)
0 (0.0)
1 (1.9)
0 (0.0)
2 (3.8)
0 (0.0)
0 (0.0)
0 (0.0)

17 (33.3)
3 (5.9)
0 (0.0)
3 (5.9)
2 (3.9)
0 (0.0)
0 (0.0)
1 (2.0)
3 (5.9)
3 (5.9)
3 (5.9)
1 (2.0)
1 (2.0)
0 (0.0)
0 (0.0)

16 (32.7)
1 (2.0)
2 (4.1)
3 (6.1)
2 (4.1)
0 (0.0)
1 (2.0)
1 (2.0)
0 (0.0)
0 (0.0)
2 (4.1)
0 (0.0)
2 (4.1)
2 (4.1)
0 (0.0)

11 (22.0)
1 (2.0)
0 (0.0)
1 (2.0)
2 (4.0)
1 (2.0)
0 (0.0)
3 (6.0)
0 (0.0)
0 (0.0)
0 (0.0)
0 (0.0)
0 (0.0)
0 (0.0)
2 (4.0)
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